1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer.
(
- Contribution to journal › Article
- 2020
-
Mark
Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment
(
- Contribution to journal › Article
- 2017
-
Mark
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98
(
- Contribution to journal › Article
-
Mark
Body constitution in young healthy women from breast cancer higher risk families in relation to smoking
2017) American Association for Cancer Research (AACR) 108th Annual Meeting 2017 In Cancer Research 77(13).(
- Contribution to journal › Published meeting abstract
- 2015
-
Mark
Tamoxifen treated patients have a better survival than patients treated with aromatase inhibitors - A population based registry study in Sweden
(
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
(
- Contribution to journal › Article